Radioprotective Effects of Amifostine, L-Carnitine and Vitamin E in Preventing Early Salivary Gland Injury due to Radioactive Iodine Treatment.
Amifostine
/ pharmacology
Animals
Carcinoma, Papillary
/ drug therapy
Carnitine
/ pharmacology
Guinea Pigs
Injections, Intramuscular
Iodine Radioisotopes
/ adverse effects
Radiation Injuries, Experimental
/ prevention & control
Radiation Protection
/ methods
Radiation-Protective Agents
/ pharmacology
Salivary Glands
/ drug effects
Thyroid Neoplasms
/ drug therapy
Vitamin E
/ pharmacology
L-Carnitine
Radioactive iodine therapy
Vitamin E
amifostine
salivary gland
thyroid cancer
Journal
Current medical imaging reviews
Titre abrégé: Curr Med Imaging Rev
Pays: United Arab Emirates
ID NLM: 101272516
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
08
2017
revised:
01
02
2018
accepted:
03
03
2018
entrez:
29
1
2020
pubmed:
29
1
2020
medline:
11
6
2020
Statut:
ppublish
Résumé
Standard treatment of differentiated thyroid cancer includes total thyroidectomy and high-dose Radioactive Iodine Therapy (RIT) for ablation of remnant thyroid tissue. When administered systemically, RIT can cause radiation-induced damage in non-targeted normal tissues. The aim of the present study was to compare the protective effects of amifostine (AMI), LCarnitine (LC), and Vitamin E (EVIT) against high dose radioactive iodine treatment induced Salivary Gland (SG) damage using SG scintigraphy and histopathological examination. Forty adult guinea pigs were studied. Twenty guinea pigs receive 555-660 MBq 131Iodine intraperitoneally (IP) to ablate the thyroid and impair the parenchymal function of the SGs. The animals were divided into eight groups as follows: (1) Group 1 (control): 1 mL IP PS (physiological saline); (2) Group 2: single dose of 200 mg/kg IP AMI one hour prior to 1 mL IP PS; (3) Group 3: 200 mg/kg IP LC and 1 mL IP PS for 10 days; (4) Group 4: 40 mg/kg intramuscular (IM) EVITand 1 mL IP PS for 10 days; (5) Group 5: IP RIT after premedication; (6) Group 6: Single dose of 200 mg/kg IP AMI one hour prior to RIT and IP RIT after premedication; (7) Group 7: IP RIT after premedication and 200 mg/kg IP LC for 10 days starting one day before RIT; and (8) Group 8: IP RIT after premedication and 40 mg/kg IM EVIT for 10 days starting one day before RIT. Scintigraphy was performed 1 month after treatment. SGs were examined by light microscopy and a histopathological scoring system was used to assess the degree of SG damage. There were significant differences in the body weight and thyroid hormone levels between the groups after treatment. The individual use of AMI, LC and EVIT for radioprotection yield different levels of protection against radioactive iodine treatment injury in SGs; however, none of the agents could provide absolute protection at the doses administered in this experimental model.
Identifiants
pubmed: 31989909
pii: CMIR-EPUB-89117
doi: 10.2174/1573405614666180314150808
doi:
Substances chimiques
Iodine Radioisotopes
0
Radiation-Protective Agents
0
Vitamin E
1406-18-4
Amifostine
M487QF2F4V
Carnitine
S7UI8SM58A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
395-404Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.